Angiotensin-neprilysin inhibition in acute decompensated heart failure
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. METHODS: We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 and 8. Key safety outcomes were the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema. RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive enalapril. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, -46.7% vs. -25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). The rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. CONCLUSIONS: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy. Rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. (Funded by Novartis; PIONEER-HF ClinicalTrials.gov number, NCT02554890 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, one-third of patients enrolled did not have a history of HF and just more than half had no previous ACEI or ARB use.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In-hospital initiation of sacubitril-valsartan resulted in a significantly greater proportional reduction in NT-proBNP compared with enalapril at weeks 4 and from baseline (mean time-averaged change in NT-proBNP, −46.7% vs 25.3%).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“This change was consistent across all subgroups, including those without previous HF and those who were RASi-naive.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In the PIONEER-HF study it was noted that in patients admitted with acute decompensated HF and reduced ejection fraction, 65% had a history of HF but only 10% were receiving an MRA at the time of admission.8”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Ambrosy, A. P., Fonarow, G. C., Butler, J., Chioncel, O., Greene, S. J., Vaduganathan, M., Nodari, S., Lam, C. S. P., Sato, N., Shah, A. N., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.053 · Cited by 2,046
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft052 · Cited by 457
Senni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Reyes, A., Majercak, I., Andreka, P., Shehova-Yankova, N., Anand, I., Yilmaz, M. B., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.548 · Cited by 236
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Ambrosy, A. P., Duffy, C. I., McCague, K., Hernandez, A. F., Rocha, R. A., & Braunwald, E. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.004 · Cited by 76
Self-citationAmbrosy, A. P., Mentz, R. J., Fiuzat, M., Cleland, J. G. F., Greene, S. J., O’Connor, C. M., Teerlink, J. R., Zannad, F. M., & Solomon, S. D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1159 · Cited by 57
Self-citation
Cited by
Items 401–500 of 999
Vergani, M., Cannistraci, R., Perseghin, G., & Ciardullo, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206225 · Cited by 21
Tang, H., Germinal, K., Milfort, A., Chen, W., Chang, S., Huang, W., Li, Y., Lu, Y., Ahmed, M. M., Kimmel, S. E., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04339-3 · Cited by 16
Chen, C., Zhong, W., Zheng, H., Zhao, W., Wang, Y., & Shen, B. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1518036 · Cited by 12
Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials
Linden, K., Mailey, J. A., Kearney, A., & Menown, I. B. A. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01355-5 · Cited by 13
Emergent expansion of clinical epigenetics in patients with cardiovascular diseases
Claudio Napoli, A., Coscioni, E., de Nigris, F., & Donatelli, F. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000843 · Cited by 12
Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan
Dillon, E., Wei, S. D., Gupta, D. K., Nian, H., Rodibaugh, B. S., Bachmann, K. N., Naftilan, A. J., Stevenson, L. W., & Brown, N. J. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.05.026 · Cited by 13
Xü, Y., Chen, Y., Zhao, J. W., Li, C., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.604017 · Cited by 14
Houchen, E., Loefroth, E., Schlienger, R. G., Proudfoot, C., Corda, S., Saha, S., Satwase, S. K., & Studer, R. L. (2022) · Cardiology and Therapy · doi:10.1007/s40119-021-00252-4 · Cited by 12
Savarese, G., Uijl, A., Ouwerkerk, W., Tromp, J., Anker, S. D., Dickstein, K., Hage, C., Lam, C. S. P., Lang, C. C., Metra, M., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13917 · Cited by 13
de la Espriella, R., Santas, E., Reiriz, I. Z., Górriz, J. L., Marcos, M. C., & Núñez, J. E. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2021.04.007 · Cited by 20
Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives
Popa, I. P., Haba, M. Ș. C., Maranducă, M. A., Tănase, D. M., Șerban, D. N., Șerban, L., Iliescu, R., & Tudorancea, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091964 · Cited by 18
Mujadzic, H., Prousi, G. S., Napier, R., Siddique, S. M., & Zaman, N. (2022) · Journal of Innovations in Cardiac Rhythm Management · doi:10.19102/icrm.2022.130905 · Cited by 14
Lai, M.-Y., Kan, W., Huang, Y.-T., Chen, J. L., & Shiao, C. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030357 · Cited by 12
Initiation of Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure With Low Cardiac Output
Martyn, T., Faulkenberg, K. D., YARANOV, D. M., Albert, C. L., Colleen, H., Menon, V., Estep, J. D., Nissen, S. E., Tang, W. H. W., & Starling, R. C. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.006 · Cited by 12
LCZ696 and preservation of renal function in heart failure: A meta-analysis of 6 randomized trials
Chen, X., Jin, C., Xie, L., & Xiang, M. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.01.2 · Cited by 13
Advances in the Management of Acute Decompensated Heart Failure
Mitter, S. S., & Pinney, S. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.03.002 · Cited by 16
Role of transthoracic echocardiogram in acute heart failure
Fitzsimons, S., & Doughty, R. N. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203081 · Cited by 13
Allen, L. A., Teerlink, J. R., Gottlieb, S. S., Ahmad, T., Lam, C. S. P., & Psotka, M. A. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008594 · Cited by 12
Liu, X., Wang, G., Xu, Q., Zhang, L., & Liu, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.943377 · Cited by 14
PIONEERing the In-Hospital Initiation of Sacubitril–Valsartan
Jarcho, J. A. (2019) · New England Journal of Medicine · doi:10.1056/nejme1900139 · Cited by 12
Diuretics and Clinical Management of Congestion in Heart Failure: A Review
Piardi, D. S., Butzke, M., & Neto, L. B. D. S. (2021) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20210009 · Cited by 12
Use of Sodium Glucose Co-Transporter 2 Inhibitors in Acute Heart Failure: A Practical Guidance
Ferreira, J. P., Pimenta, J. M., Moura, B., Aguíar, C., & Franco, F. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14090 · Cited by 13
New Strategies to Prevent Rehospitalizations for Heart Failure
Diamond, J. E., & DeVore, A. D. (2022) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-022-00969-y · Cited by 21
Self-citationJiang, J., Gao, J., Zhang, X., Li, Y., Dang, H., Liu, Y., & Chen, W. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1097066 · Cited by 13
R2R01: A long‐acting single‐chain peptide agonist of RXFP1 for renal and cardiovascular diseases
Poirier, B., Pasquier, O., Chénedé, X., Corbier, A., Prigent, P., Azam, A., Bernard, C., Guillotel, M., Gillot, F., Riva, L., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16338 · Cited by 12
An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease
Tumelty, E. H., Chung, I., Hussain, S. A., Ali, M. A., Addada, H., & Banerjee, D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2504144 · Cited by 13
Geng, Q., Li, S., Wang, Z., & Ren, Y. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.05.048 · Cited by 12
Understanding the Results of the PARAGON-HF Trial
Ferrari, R., Fucili, A., & Rapezzi, C. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1797 · Cited by 11
Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
Villani, A., Ravaro, S., Cerea, P., Caravita, S., Ciambellotti, F., Branzi, G., Munforti, C., Parati, G., & Malfatto, G. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001000 · Cited by 13
Chng, B. L. K., Hon, J. S., Chan, H., Zheng, Y., Gao, F., Teo, L. Y., & Sim, K. L. D. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.08.014 · Cited by 14
Lin, W., Chung, F., Liao, C., Huang, J., Liang, H.-W., Lee, Y., Lin, P.-L., Chiou, W., Hsu, C., & Chang, H. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000578 · Cited by 11
Tanaka, A., Toyoda, S., Imai, T., Shiina, K., Tomiyama, H., Matsuzawa, Y., Okumura, T., Kanzaki, Y., Onishi, K., Kiyosue, A., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01369-5 · Cited by 13
Haemodynamic Effects of Sacubitril/Valsartan in Advanced Heart Failure
Gentile, P., Cantone, R., Perna, E., Ammirati, E., Varrenti, M., D’Angelo, L., Verde, A., Foti, G., Masciocco, G., Garascia, A., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13755 · Cited by 12
Maizels, L., Wasserstrum, Y., Fishman, B., Segev, A., Ben‐Nun, D., Younis, A., Freimark, D., Mazin, I., & Grupper, A. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13801 · Cited by 12
Lin, Y., Zhang, H., Zhao, S., Chen, L., Li, J., Wang, X., & Tian, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.882089 · Cited by 12
Mapelli, M., Mattavelli, I., Paolillo, S., Salvioni, E., Magrì, D., Galotta, A., Martino, F. D., Mantegazza, V., Vignati, C., Esposito, I., et al. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03527-y · Cited by 11
Sohani, Z. N., Behlouli, H., de Moura, C. S., Abrahamowicz, M., & Pilote, L. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028865 · Cited by 12
der Linden, L. R. V., Hias, J., Walgraeve, K., Petrović, M., Tournoy, J., Vandenbriele, C., & Aelst, L. N. L. V. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01046-0 · Cited by 13
Multiscale mapping of transcriptomic signatures for cardiotoxic drugs
Hansen, J., Xiong, Y., Siddiq, M. M., Dhanan, P., Hu, B., Shewale, B., Yadaw, A. S., Jayaraman, G., Tolentino, R. E., Chen, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52145-4 · Cited by 16
Novel Potassium Binders as Enabling Therapy in Heart Failure
Butler, J., Khan, M. S., & Anker, S. D. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1474 · Cited by 11
Risk Factors for Intolerance of Inpatient Sacubitril/Valsartan Initiation
Akerman, C. C., & Beavers, J. C. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019878948 · Cited by 11
Contemporary approach to treating heart failure
Brann, A. M., Tran, H. A., & Greenberg, B. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.011 · Cited by 15
Peppin, K. L., Tellor, K. B., Armbruster, A. L., & Schwarze, M. W. (2020) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2019.1708638 · Cited by 11
Mentz, R. J., Xu, H., O'Brien, E. C., Thomas, L. E., Alexy, T., Gupta, B. P., Vilaro, J. R., Lala, A., DeVore, A. D., Dhingra, R., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.09.012 · Cited by 15
Self-citationDoes sacubitril/valsartan work in acute myocardial infarction? The PARADISE-AMI study
Gatto, L. (2021) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab098 · Cited by 12
Gilstrap, L. G., Zipkin, R. J., Barnes, J. A., King, A. C., O’Malley, A. J., Gaziano, T. A., & Tosteson, A. N. A. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.04.007 · Cited by 11
Zhang, L., Yan, K., Zhao, H., Shou, Y., Chen, T., & Chen, J. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-210 · Cited by 10
Recent advances in the treatment of chronic heart failure
Buckley, L. F., & Shah, A. M. (2019) · F1000Research · doi:10.12688/f1000research.20447.1 · Cited by 15
Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
Carballo, D., Stirnemann, J., Garin, N., Marti, C., Serratrice, J., & Carballo, S. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12676 · Cited by 11
Lung Ultrasound: Monitoring Congestion in Patients with Heart Failure
Platz, E., Solomon, S. D., & McMurray, J. J. V. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1636 · Cited by 11
Proposed New Conceptualization for Definition of Decompensated HF
Bozkurt, B. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.02.001 · Cited by 12
2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease
Williams, M. S., Levine, G. N., Kalra, D. K., Agarwala, A., Baptiste, D., Cigarroa, J. E., Diekemper, R. L., Foster, M., Gulati, M., Henry, T. D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.001 · Cited by 16
Capric, V., Chandrakumar, H. P., Celenza-Salvatore, J., & Makaryus, A. N. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96415 · Cited by 11
Kim, D., Jang, G., Hwang, J., Wei, X., Kim, H., Son, J., Rhee, S. J., Yun, K. H., Oh, S., Oh, C., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122629 · Cited by 12
Esteban‐Fernández, A., Otero, I. G., López‐Fernández, S., Santamarta, M. R., Pastor‐Pérez, F. J., Fluvià-Brugués, P., Pérez-Rivera, J.-Á., López, A. L., García‐Pinilla, J. M., Palomas, J. L. B., et al. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02241-0 · Cited by 13
Summary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines
Badger, S., McVeigh, J., & Indraratna, P. (2023) · Cardiology and Therapy · doi:10.1007/s40119-023-00328-3 · Cited by 14
Nesterov, S. V., Räty, J., Nammas, W., Maaniitty, T., Galloo, X., Stassen, J., Laurila, S., Vasankari, T., Huusko, J., Bax, J. J., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3072 · Cited by 11
New and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 15
Wang, H., Gao, C., Guignard‐Duff, M., Cole, C., Hall, C., Baruah, R., Das, S., Gao, H., Mamza, J. B., Lang, C. C., et al. (2025) · Heart · doi:10.1136/heartjnl-2024-324160 · Cited by 13
Noiri, J., Fujimoto, W., Takemoto, M., Kuroda, K., Yamashita, S., Imanishi, J., Iwasaki, M., Todoroki, T., Okuda, M., Nagao, M., et al. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0002 · Cited by 12
Laborante, R., Restivo, A., Mele, D., Francesco, M. D., Ferreira, J. P., Vasques‐Nóvoa, F., Andreini, D., Volterrani, M., Patti, G., & D’Amario, D. (2025) · Cardiac failure review · doi:10.15420/cfr.2025.01 · Cited by 12
Caraballo, C., Khera, R., Jones, P. G., Decker, C., Schulz, W. L., Spertus, J. A., & Krumholz, H. M. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.006231 · Cited by 12
Zhang, F., Zhang, T., Yang, S., Wang, D., Zhuo, Q., Qin, X., Gong, N., & Ai, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.831541 · Cited by 10
Sacubitril/valsartan in Heart Failure and Beyond—From Molecular Mechanisms to Clinical Relevance
Muric, M. D., Srejovic, I. M., Joksimović, J., Sretenovic, J. Z., Jeremic, J. N., Čekerevac, I., Simovic, S. M., Djoković, D., Muric, N. N., Stojić, V., et al. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2307238 · Cited by 13
Chimed, S., Stassen, J., Galloo, X., Meucci, M. C., van der Bijl, P., Knuuti, J. M., Delgado, V., Marsan, N. A., & Bax, J. J. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.08.035 · Cited by 8
Liu, H., Su, Y., Shen, J., Jiao, Y., Li, Y., Liu, B., Hou, X., Jin, Q., Chen, Y., Sun, Z., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14646 · Cited by 11
Sciatti, E., Dallapellegrina, L., Metra, M., & Lombardi, C. (2019) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000850 · Cited by 12
Георгиевна, В. Н. (2019) · Kardiologiia · doi:10.18087/cardio.n613 · Cited by 10
Randhawa, V. K., West, L. M., Luthman, J., Estep, J. D., Soltesz, E. G., & Starling, R. C. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1873 · Cited by 10
Alishetti, S., Braghieri, L., Jennings, D. L., Uriel, N. Y., Colombo, P. C., & yuzefpolskaya, M. (2021) · The International Journal of Artificial Organs · doi:10.1177/0391398821989066 · Cited by 10
Renal protective effect of sacubitril/valsartan in patients with heart failure
Hsieh, H., Chen, C., Chen, C.-H., Hsu, S., Huang, W., Sue, Y., Lin, F., Shih, C., Chang, Y.-C., Huang, P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84118-8 · Cited by 13
Ntalianis, A., Chrysohoou, C. A., Giannakoulas, G. A., Giamouzis, G., Karavidas, A. I., Naka, A., Papadopoulos, C. H., Patsilinakos, S. P., Parissis, J., Tziakas, D. N., et al. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10115-8 · Cited by 11
Proudfoot, C., Gautam, R., Cristino, J. R., Agrawal, R., Thakur, L., & Tolley, K. H. (2022) · The European Journal of Health Economics · doi:10.1007/s10198-022-01485-3 · Cited by 10
Bhatt, A. S., Vaduganathan, M., Zhuo, M., Fu, E. L., Solomon, S. D., & Desai, R. J. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.09.004 · Cited by 10
Chronic heart failure: epidemiology, investigation and management
Beggs, S. A. S., McDonagh, T. A., & Gardner, R. S. (2022) · Medicine · doi:10.1016/j.mpmed.2022.05.002 · Cited by 8
Martínez-Esteban, M. D., Vázquez-Sánchez, T., Alvarez, R. D. P., Moreno-Ortiz, A., Alonso-Titos, J., Martín-Reyes, G., Esteban, P. R., Román, D. G., & Hernández, D. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02919-z · Cited by 13
Quality of life in heart failure: New data, new drugs and devices
Major, K., Bodys-Pełka, A., Grabowski, M., & Lelonek, M. (2024) · Cardiology Journal · doi:10.5603/cj.92243 · Cited by 12
Fudim, M., Cyr, D. D., Ward, J. H., Hernandez, A. F., Lepage, S., Morrow, D. A., Sharma, K., Claggett, B. L., Starling, R. C., Velazquez, E. J., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.04.030 · Cited by 9
Self-citationPrognostic value of NT-proBNP in the new era of heart failure treatment
Nguyen, D. V., Nguyen, S. V., Pham, A. L., Nguyen, B. T., & Hoang, S. V. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309948 · Cited by 15
Diuretic Potentiation Strategies in Acute Heart Failure
Siddiqi, T. J., Packer, M., Ezekowitz, J. A., Fonarow, G. C., Greene, S. J., Kittleson, M. M., Khan, M. S., Mentz, R. J., Testani, J. M., Voors, A. A., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.09.017 · Cited by 9
Sacubitril/Valsartan vs ACE Inhibitors or ARBs
Evbayekha, E. O., Idowu, A. B., & LaRue, S. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101598 · Cited by 11
Huang, N., Xu, Y., Liu, C., Liu, Y., Fan, Y., Li, Z., Zhang, D., Mao, H., & Chen, W. (2025) · Drugs · doi:10.1007/s40265-025-02198-6 · Cited by 12
Covic, A. C., Voroneanu, L. E., Stefan, A.-E., Brinza, C., Covic, A. M., Kanbay, M., Scripcariu, V., Iliescu, Ș., & Burlacu, A. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf224 · Cited by 9
Salah, H. M., Ambrosy, A. P., Biegus, J., Bocchi, E. A., Butler, J., Chioncel, O. D., Cotter, G., Davison, B. A., Dzudié, A., Freund, Y., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.09.020 · Cited by 11
Self-citationChioncel, O. D., Savarese, G., Laroche, C., Amir, O., Tokmakova, M. P., Cannata, A. N., Do, D. L., Kafafy, T. A., Krejčí, J., Moura, B., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70065 · Cited by 13
Kobayashi, M., Bozkurt, B., Myhre, P. L., López‐Azor, J. C., Guzik, M., Iwanek, G., Baudry, G., Marcos, M. C., Miró, Ò., Dauw, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70079 · Cited by 11
Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease
Lópes, R. D., Bocchi, E. A., Echeverría, L. E., Demacq, C., Silva, P. G. M. D. B. E., Barbosa, L. M., Damiani, L. P., Sayyed, S., Yoshida, L. A. F., Furtado, R. H. M., et al. (2025) · JAMA · doi:10.1001/jama.2025.19808 · Cited by 9
Self-citationMedical management of acute heart failure
Kamran, H., & Tang, W. H. W. (2021) · Faculty Reviews · doi:10.12703/r/10-82 · Cited by 14
Chen, W., Jiang, J., Gao, J., Zhang, X., Li, Y., Liu, Y., & Dang, H. (2023) · Clinical Cardiology · doi:10.1002/clc.23971 · Cited by 11
Butt, J. H., Ibrahim, W., Dewan, P., Desai, A. S., Køber, L., PRESCOTT, M. F., Lefkowitz, M. P., Rouleau, J. L., Solomon, S. D., Zile, M. R., et al. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.010111 · Cited by 9
Olson, M., Thompson, Z., Xie, L. X., & Nair, A. P. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01907-5 · Cited by 8
Hyun, J., Cho, J. Y., Youn, J., Kim, D., Cho, D., Park, S. M., Jung, M., Cho, H., Park, S., Choi, J., et al. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0115 · Cited by 8
Heart Failure: Recent Advances and Breakthroughs
Sebastian, S. A., Co, E. L., Mahtani, A. U., Padda, I., Anam, M., Mathew, S. S., Shahzadi, A., Niazi, M., Pawar, S., & Johal, G. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101634 · Cited by 11
Medical Management and Device-Based Therapies in Chronic Heart Failure
Nguyen, A. H., Hurwitz, M., Abraham, J. A., Blumer, V. L., Flanagan, M. C., Garan, A. R., Kanwar, M. K., Kataria, R., Kennedy, J. L. W., Kochar, A., et al. (2023) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2023.101206 · Cited by 14
Kommu, S., & Berg, R. L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061572 · Cited by 14
Quiroga, B., de Santos, A., Sapiencia, D., Catala, Y. S., & Chiva, V. Á. (2019) · Nefrología · doi:10.1016/j.nefro.2019.01.005 · Cited by 9
ARNIs: balancing “the good and the bad” of neuroendocrine response to HF
the “Italian-Portuguese Action on Heart Failure” Group, Ferrari, R., Cardoso, J., Fonseca, C., Aguíar, C., Moreira, J. I., Fucili, A., & Rapezzi, C. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01547-2 · Cited by 9
Updates in pharmacotherapy of heart failure with reduced ejection fraction
Espinoza, C., Alkhateeb, H., & Siddiqui, T. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4640 · Cited by 9
Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis
Pereira, G. M. E., Duarte, G. S., Katerenchuk, V., Costa, J. N., David, C., Ferreira, J. J., Pinto, F. J., & Caldeira, D. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1877658 · Cited by 10
Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction
Kim, I. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.03.001 · Cited by 11
Metadata
- Authors
- Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (E.J.V.); the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston (D.A.M., E.B.); Duke Clinical Research Institute, Duke University, Durham, NC (A.D.D.); Novartis Pharmaceuticals, East Hanover, NJ (C.I.D., K.M., R.R.); and the Division of Cardiology, Permanente...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-07
- Volume
- 380
- Issue
- 6
- Pages
- 539-548
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899841238
- Cited by
- 1,260
- References
- 16
- Citations by year
- 2026: 74 · 2025: 139 · 2024: 136 · 2023: 215 · 2022: 199 · 2021: 189 · 2020: 171 · 2019: 128
- FWCI
- 93.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- acute decompensated heart failure, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, NT-proBNP, renal function, hyperkalemia, angioedema, symptomatic hypotension, drug safety, hospitalization, hemodynamic stabilization, natriuretic peptides
- MeSH terms
- Valsartan, Acute Disease, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiac Output, Low, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Humans, Male, Middle Aged, Peptide Fragments, Stroke Volume, Tetrazoles, Neprilysin, Natriuretic Peptide, Brain, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.